Twenty Questions for Phosphagenics

Apologies in advance for what is a fairly long post… In the usual stream of announcements and news feeds yesterday, I read the ASX release from Phosphagenics (ASX : POH) regarding their Oxycodone PHN study. Now I don’t comment much on this company, despite the fact that they are fairly visible in the public domain. About…

The Incest of ASX Biopharma

It’s pretty hard to beat the Brits when it comes to situational comedy. As a dual-Australian/Canadian national educated in the UK, I suppose I have an intrinsic affinity for that dry, offhand style of humour. A few years ago, I stumbled across a brilliant comedy skit that visually captures precisely the fundamental reason why ASX biopharma is…

ACL : Erratum (Mr. Ken Poutakidis)

By way of follow-up to my previous post on Alchemia (ASX : ACL), I have been informed that my implied statement that Mr Ken Poutakidis, who recently joined the struggling board of ACL, was previously a director of Phosphagenics (ASX : POH) is in fact incorrect. I made a determination on the basis of reasonable information that was…

The Next Great ASX Biotech?

Every once in a while I read a news item that leaves me in a state of semi-shock and, let’s face it, that is a pretty high bar given the messed-up world we live in. This weekend, I spent a bit of time catching up on current affairs (as one does on a lazy Sunday morning) and…

Phosphagenics : Tough Times

Ever since Ross Murdoch sent out his pre-AGM note to Phosphagenics (ASX:POH) shareholders on the back-end of a fairly negative announcement that there would be at least a further 12 month delay in clinical development of the Oxymorphone product due to a formulation issue, there has been a lot of hoo-hah from shareholders. Shareholders that…